CHILDHOOD-ONSET NEURODEGENERATION WITH BRAIN ATROPHY (CONDBA)

Clinical trials for CHILDHOOD-ONSET NEURODEGENERATION WITH BRAIN ATROPHY (CONDBA) explained in plain language.

Never miss a new study

Get alerted when new CHILDHOOD-ONSET NEURODEGENERATION WITH BRAIN ATROPHY (CONDBA) trials appear

Sign up with your email to follow new studies for CHILDHOOD-ONSET NEURODEGENERATION WITH BRAIN ATROPHY (CONDBA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

One-of-a-kind drug aims to slow rare brain disease in a single child

Disease control Ongoing

This study tests a personalized medicine called an antisense oligonucleotide (ASO) designed for one child with a rare genetic brain disease (CONDBA) that causes brain shrinkage and movement problems. The goal is to see if the drug can improve or stabilize motor skills, coordinati…

Matched conditions: CHILDHOOD-ONSET NEURODEGENERATION WITH BRAIN ATROPHY (CONDBA)

Phase: PHASE1, PHASE2 • Sponsor: n-Lorem Foundation • Aim: Disease control

Last updated May 17, 2026 13:28 UTC

CHILDHOOD-ONSET NEURODEGENERATION WITH BRAIN ATROPHY (CONDBA)

Get alerted when new CHILDHOOD-ONSET NEURODEGENERATION WITH BRAIN ATROPHY (CONDBA) trials appear

One-of-a-kind drug aims to slow rare brain disease in a single child